Recently, the interleukin-like epithelial-mesenchymal transition (EMT) inducer (ILEI) has emerged as a new cytokine that can activate STAT3 and drive both EMT and breast cancer stem cell formation through LIFR [109]. This evidence concerns the gene STAT3 and breast carcinoma.